Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury

Ronald Carnemolla, Carlos H. Villa, Colin F. Greineder, Sergei Zaitsev, Kruti R. Patel, M. Anna Kowalska, Dmitriy N. Atochin, Douglas B. Cines, Don L. Siegel, Charles T. Esmon, Vladimir R. Muzykantov

Результат исследований: Материалы для журналаСтатья

6 Цитирования (Scopus)

Выдержка

Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red bloodcells (RBCs) to improvepharmacokinetics andantithrombotic effectswithout increasingbleeding.Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTMdid not, and augmentedAPCproduction by thrombin~50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies thatblockAPCanticoagulant activity suppress theprophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM wasmore effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.-Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitseva, S., Patel, K. R., Kowalska, M. A., Atochin, D.N., Cines, D. B., Siegel, D. L., Esmon, C.T., Muzykantov, V.R.Targeting thrombomodulinto circulating red blood cells augments its protective effects inmodels of endotoxemia and ischemia-reperfusion injury.

Язык оригиналаАнглийский
Страницы (с-по)761-770
Число страниц10
ЖурналFASEB Journal
Том31
Номер выпуска2
DOI
СостояниеОпубликовано - 1 фев 2017
Опубликовано для внешнего пользованияДа

Отпечаток

Thrombomodulin
Endotoxemia
Reperfusion Injury
Blood
Erythrocytes
Cells
Protein C
Endotoxins
Inflammation
Single-Chain Antibodies
Coagulation
Brain Ischemia
Recombinant Proteins
Thrombin
Liver

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Цитировать

Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitsev, S., Patel, K. R., Kowalska, M. A., ... Muzykantov, V. R. (2017). Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. FASEB Journal, 31(2), 761-770. https://doi.org/10.1096/fj.201600912R

Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. / Carnemolla, Ronald; Villa, Carlos H.; Greineder, Colin F.; Zaitsev, Sergei; Patel, Kruti R.; Kowalska, M. Anna; Atochin, Dmitriy N.; Cines, Douglas B.; Siegel, Don L.; Esmon, Charles T.; Muzykantov, Vladimir R.

В: FASEB Journal, Том 31, № 2, 01.02.2017, стр. 761-770.

Результат исследований: Материалы для журналаСтатья

Carnemolla, R, Villa, CH, Greineder, CF, Zaitsev, S, Patel, KR, Kowalska, MA, Atochin, DN, Cines, DB, Siegel, DL, Esmon, CT & Muzykantov, VR 2017, 'Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury', FASEB Journal, том. 31, № 2, стр. 761-770. https://doi.org/10.1096/fj.201600912R
Carnemolla, Ronald ; Villa, Carlos H. ; Greineder, Colin F. ; Zaitsev, Sergei ; Patel, Kruti R. ; Kowalska, M. Anna ; Atochin, Dmitriy N. ; Cines, Douglas B. ; Siegel, Don L. ; Esmon, Charles T. ; Muzykantov, Vladimir R. / Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury. В: FASEB Journal. 2017 ; Том 31, № 2. стр. 761-770.
@article{8447d7238e5e4dfb84709dfe95095ca8,
title = "Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury",
abstract = "Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red bloodcells (RBCs) to improvepharmacokinetics andantithrombotic effectswithout increasingbleeding.Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTMdid not, and augmentedAPCproduction by thrombin~50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies thatblockAPCanticoagulant activity suppress theprophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM wasmore effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.-Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitseva, S., Patel, K. R., Kowalska, M. A., Atochin, D.N., Cines, D. B., Siegel, D. L., Esmon, C.T., Muzykantov, V.R.Targeting thrombomodulinto circulating red blood cells augments its protective effects inmodels of endotoxemia and ischemia-reperfusion injury.",
keywords = "Coagulation, Drug delivery, Inflammation, Pharmacokinetics, Sepsis",
author = "Ronald Carnemolla and Villa, {Carlos H.} and Greineder, {Colin F.} and Sergei Zaitsev and Patel, {Kruti R.} and Kowalska, {M. Anna} and Atochin, {Dmitriy N.} and Cines, {Douglas B.} and Siegel, {Don L.} and Esmon, {Charles T.} and Muzykantov, {Vladimir R.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1096/fj.201600912R",
language = "English",
volume = "31",
pages = "761--770",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "2",

}

TY - JOUR

T1 - Targeting thrombomodulin to circulating red blood cells augments its protective effects in models of endotoxemia and ischemia-reperfusion injury

AU - Carnemolla, Ronald

AU - Villa, Carlos H.

AU - Greineder, Colin F.

AU - Zaitsev, Sergei

AU - Patel, Kruti R.

AU - Kowalska, M. Anna

AU - Atochin, Dmitriy N.

AU - Cines, Douglas B.

AU - Siegel, Don L.

AU - Esmon, Charles T.

AU - Muzykantov, Vladimir R.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red bloodcells (RBCs) to improvepharmacokinetics andantithrombotic effectswithout increasingbleeding.Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTMdid not, and augmentedAPCproduction by thrombin~50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies thatblockAPCanticoagulant activity suppress theprophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM wasmore effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.-Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitseva, S., Patel, K. R., Kowalska, M. A., Atochin, D.N., Cines, D. B., Siegel, D. L., Esmon, C.T., Muzykantov, V.R.Targeting thrombomodulinto circulating red blood cells augments its protective effects inmodels of endotoxemia and ischemia-reperfusion injury.

AB - Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red bloodcells (RBCs) to improvepharmacokinetics andantithrombotic effectswithout increasingbleeding.Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTMdid not, and augmentedAPCproduction by thrombin~50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies thatblockAPCanticoagulant activity suppress theprophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM wasmore effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.-Carnemolla, R., Villa, C. H., Greineder, C. F., Zaitseva, S., Patel, K. R., Kowalska, M. A., Atochin, D.N., Cines, D. B., Siegel, D. L., Esmon, C.T., Muzykantov, V.R.Targeting thrombomodulinto circulating red blood cells augments its protective effects inmodels of endotoxemia and ischemia-reperfusion injury.

KW - Coagulation

KW - Drug delivery

KW - Inflammation

KW - Pharmacokinetics

KW - Sepsis

UR - http://www.scopus.com/inward/record.url?scp=85011255374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011255374&partnerID=8YFLogxK

U2 - 10.1096/fj.201600912R

DO - 10.1096/fj.201600912R

M3 - Article

AN - SCOPUS:85011255374

VL - 31

SP - 761

EP - 770

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 2

ER -